Tempest Therapeutics, Inc. — Director's Dealing 2019

Aug 21, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Millendo Therapeutics, Inc. (MLND)
CIK: 0001544227
Period of Report: 2019-08-16

Reporting Person: Zeidan Ryan (Chief Development Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Option (right to buy)	$16.40	2028-08-23	Common Stock (62569)		Direct
Employee Stock Option (right to buy)	$8.80	2029-01-14	Common Stock (40000)		Direct
Employee Stock Option (right to buy)	$11.59	2029-06-19	Common Stock (5000)		Direct

Footnotes

F1: Twenty-five percent (25%) of the shares subject to the option vested on June 18, 2019, and one thirty-sixth (1/36th) of the remaining shares
subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

F2: Twenty-five percent (25%) of the shares subject to the option vest on January 15, 2020, and one thirty-sixth (1/36th) of the remaining shares
subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

F3: Twenty-five percent (25%) of the shares subject to the option vest on June 20, 2020, and one thirty-sixth (1/36th) of the remaining shares
subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.